EUA For COVID-19 Vaccine Would Mean Fewer Patient-Years Of Follow-Up But More Pharmacovigilance
US FDA plans to leverage large safety surveillance databases to make up for the fact that a vaccine authorized for emergency use likely would have only one-quarter to one-half as much safety data follow-up as a typical vaccine licensed under a BLA, says CBER director Peter Marks.
You may also be interested in...
COVID-19 Vaccine EUA Process Compresses Advisory Committee Prep Too
US FDA wants briefing documents when EUA is submitted to accommodate timely advisory committee reviews; unlike traditional assessment process, the agency does not appear interested in engaging in back-and-forth discussions with sponsors about portions of the briefing document that should be made public or redacted.
Transparency, And A Mirror: US FDA Advice On COVID-19 Vaccine EUAs Finally Published – Twice
Everyone but Donald Trump seems happy that the guidance is finally here, with release appearing to be driven by FDA's disclosure of advisory committee materials.
US FDA ‘Flexible’ With Vaccine Safety Data Requirements, CBER’s Peter Marks Says
The median of two months of follow-up is not absolute, but agency flexibility is limited.